子宫内膜异位症是育龄妇女人群中较常见的一种疾病,其发病率为10%~15%〔1〕。从病理学上看,子宫内膜异位症为雌激素依赖性疾病,异位的内膜含有雌激素受体以及孕激素受体,而雌激素可以引起内膜增生,雄性激素抑制内膜增生,高效孕激素使得异位内膜蜕膜变,最终发生萎缩,因此应该建立持续性低雌激素以及高孕激素或者高雄激素环境,才能够达到抑制子宫内膜异位症的目的〔2-3〕。米非司酮是由法国的Roussel公司首先研发 Endometriosis is a more common disease among women of childbearing age with an incidence of 10% to 15% [1]. Pathologically, endometriosis is an estrogen-dependent disease. Ectopic endometrium contains estrogen receptors and progesterone receptors. Estrogen can cause intimal hyperplasia and androgen inhibits intimal hyperplasia , Efficient progesterone makes ectopic endometrial decidua change, the final occurrence of atrophy, it should establish a sustained low estrogen and high progesterone or androgen environment, in order to achieve the purpose of inhibiting endometriosis 〔2-3 ]. Mifepristone was first developed by French company Roussel